The Indian Patent Office has rejected a patent application filed by the US based Global Alliance for TB Drug Development for BPaL, a combination therapy used to treat tuberculosis. The decision was based on grounds including lack of novelty, lack of inventive step, non patentability and insufficient disclosure, according to the reported details of the ruling.
The decision could have important implications for access to tuberculosis treatment in India and other countries with a high burden of the disease. Health experts say the rejection may create opportunities for Indian pharmaceutical manufacturers to develop and market more affordable generic versions, subject to applicable patent laws and regulatory requirements.
BPaL is a combination of three medicines, bedaquiline, pretomanid and linezolid. It is used in a six month, all oral treatment regimen for certain patients with tuberculosis, including those who require specialised treatment for drug resistant forms of the disease. Compared with some older treatment approaches, the shorter regimen can reduce the duration of treatment and the burden associated with taking medicines for an extended period.
Tuberculosis remains a major public health challenge in India and several other countries. Timely diagnosis, appropriate treatment and access to effective medicines are essential to controlling the disease. However, the cost of medicines and the length of treatment can create difficulties for patients and healthcare systems. The availability of affordable treatment options is therefore an important part of efforts to improve treatment access and outcomes.
The Indian government provides BPaL based treatment through the National TB Elimination Programme. Despite this support, treatment costs and access to medicines remain important concerns across the wider healthcare system. The possible entry of additional generic manufacturers could help expand supply and increase competition, provided that the relevant legal and regulatory requirements are met.
The patent application was challenged through pre grant oppositions filed by public health groups and individuals. One opposition was submitted by Eldred Tellis of Sankalp Rehabilitation Trust and tuberculosis survivor Ganesh Acharya, with support from the Lawyers’ Collective and the Médecins Sans Frontières Access Campaign. A separate opposition was filed by the Delhi Network of Positive People, supported by the Third World Network.
A pre grant opposition allows interested parties to raise objections to a patent application before the patent is granted. Under Indian patent law, these objections may address whether the claimed invention is genuinely new, whether it involves an inventive step, whether it is eligible for patent protection and whether the application provides sufficient information about the invention.
According to the reported details, the Patent Controller accepted objections concerning lack of novelty, lack of inventive step, non patentability and insufficient disclosure. The application was refused under Section 15 of the Indian Patents Act.
The opponents argued that scientific research published as early as 2015 had already disclosed the combination of medicines and its use in a shorter treatment regimen. Such arguments are relevant to patent examination because an application must satisfy the legal requirements for protection. If the claimed invention has already been disclosed in earlier research or other relevant public material, that information may affect whether a patent can be granted.
Novelty and inventive step are distinct legal requirements. Novelty concerns whether the claimed invention was already disclosed in existing information before the relevant date. Inventive step concerns whether the claimed invention represents a sufficient advance over what was already known. Patent authorities assess the application and the evidence submitted by the applicant and any opponents before making a decision.
The rejection may be significant for pharmaceutical companies interested in producing generic versions of the treatment. If no other applicable legal barriers prevent production and marketing, generic manufacturers may have an opportunity to develop alternative products. Greater competition can sometimes reduce medicine prices and improve supply, potentially benefiting healthcare programmes and patients.
However, the patent rejection does not automatically mean that generic versions will become available immediately or that their prices will necessarily fall. The outcome depends on the wider intellectual property position, the status of any related patents, manufacturing capacity, regulatory approvals and the ability of companies to supply medicines that meet required quality standards. Any further legal proceedings or challenges could also affect the timeline.
The reported information also highlights the use of newer tuberculosis treatment options under the National TB Elimination Programme. More than 15,000 patients have reportedly begun treatment with BPaLM, a related regimen that adds moxifloxacin to bedaquiline, pretomanid and linezolid. The figure should be considered alongside official programme data, including the reporting period and the eligibility criteria for treatment.
BPaL and BPaLM are intended for patients who meet the relevant clinical criteria. The appropriate regimen depends on the form of tuberculosis, drug susceptibility, a patient’s medical condition and the guidance followed by healthcare professionals. Patients should not start, stop or change tuberculosis medicines without consulting their treating medical team.
The broader issue is the balance between intellectual property rights, pharmaceutical research and access to essential medicines. Patent protection can support innovation by providing incentives for the development of new treatments. At the same time, patent examination helps ensure that exclusive rights are granted only when the legal criteria are satisfied. Where generic production is permitted, competition may improve the affordability and availability of medicines.
For India, access to effective tuberculosis treatment is closely connected to the country’s public health goals. Affordable medicines can help healthcare programmes use available resources efficiently and support patients who need sustained treatment. Nevertheless, affordability must be accompanied by reliable supply, appropriate clinical supervision and strict quality controls.
The rejection of the BPaL patent application could become an important development in discussions about access to tuberculosis medicines. Its practical effect will depend on the final legal position, the actions of pharmaceutical manufacturers and the regulatory process. For now, the decision highlights the importance of patent examination and public health considerations in determining how essential medicines may be developed, supplied and accessed.
The priority remains ensuring that people with tuberculosis receive appropriate, safe and effective treatment without unnecessary financial or practical barriers. Any potential expansion of generic supply will need to meet that objective while complying with Indian law and established pharmaceutical quality requirements.
